Xenograft Implants for Human Use

The availability of a biologic matrix provides surgeons with an expanded supply of sterile tissue that is a natural alternative to autograft, allograft, and synthetic resorbable materials.

RTI has also launched BioSet DBM, which consists of demineralized bone matrix (DBM) in a purified gelatin carrier, available in various sizes and forms. It is used as a bone void filler in many types of surgical procedures. Both products were launched at annual meeting of the American Association of Orthopaedic Surgeons held in March 2006 in Chicago (Illinois, USA).

The official launch of these two new implant lines illustrates how Regeneration Technologies is once again leading the biologics evolution in health care, said Brian K. Hutchison, RTI chairman, president, and CEO. RTI remains committed to enhancing the lives of patients by pioneering health solutions through regenerative medicine.

RTI also holds the patents on BioCleanse, a tissue sterilization process that was used to sterilize the implants, which has been validated to eliminate viruses, bacteria, fungi, and spores from tissue without impacting the structural or biomechanical integrity of the tissue.



Related Links:
Regeneration Technologies